Biomarin Pharmaceutical (BMRN) Revenue: 2009-2025
Historic Revenue for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to $776.1 million.
- Biomarin Pharmaceutical's Revenue rose 4.08% to $776.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 billion, marking a year-over-year increase of 12.39%. This contributed to the annual value of $2.9 billion for FY2024, which is 17.97% up from last year.
- Per Biomarin Pharmaceutical's latest filing, its Revenue stood at $776.1 million for Q3 2025, which was down 5.97% from $825.4 million recorded in Q2 2025.
- Biomarin Pharmaceutical's Revenue's 5-year high stood at $825.4 million during Q2 2025, with a 5-year trough of $408.7 million in Q3 2021.
- In the last 3 years, Biomarin Pharmaceutical's Revenue had a median value of $712.0 million in 2024 and averaged $692.7 million.
- Per our database at Business Quant, Biomarin Pharmaceutical's Revenue fell by 14.27% in 2021 and then increased by 28.28% in 2024.
- Biomarin Pharmaceutical's Revenue (Quarterly) stood at $449.8 million in 2021, then increased by 19.50% to $537.5 million in 2022, then rose by 20.22% to $646.2 million in 2023, then grew by 15.65% to $747.3 million in 2024, then climbed by 4.08% to $776.1 million in 2025.
- Its Revenue was $776.1 million in Q3 2025, compared to $825.4 million in Q2 2025 and $745.1 million in Q1 2025.